Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines

Welf Prager
Dermatologikum Hamburg, Hamburg, Germany

Objectives: This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™; botulinum toxin type A [150 kDa]), which is free from complexing proteins, and discusses its efficacy and safety in the treatment of glabellar frown lines. Differences between incobotulinumtoxinA and other commercially available botulinum neurotoxin type A (BoNT/A) products that have been approved by the European Medicines Agency, US Food and Drug Administration, and other regulatory agencies for this indication are also discussed.

Findings: IncobotulinumtoxinA differs from other commercially available BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, minimizing foreign protein load. IncobotulinumtoxinA is commonly used at a 1:1 dose ratio with onabotulinumtoxinA and displays comparable efficacy and safety; furthermore, it is associated with early onset and long duration of effect, and high levels of subject satisfaction. In terms of practical considerations, incobotulinumtoxinA does not require cold storage and demonstrates low spread, enabling precise treatment and good tolerability.

Conclusion: IncobotulinumtoxinA is an efficacious and well-tolerated treatment for glabellar frown lines. It differs from other BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, which is relevant clinically, as this reduces the foreign protein load and minimizes the risk of neutralizing antibody production. In practical terms, incobotulinumtoxinA has a long shelf-life, remaining stable without the need for refrigeration, and due to its limited spread is a precise localized treatment.

Keywords: clinical use, glabellar frown lines, incobotulinumtoxinA, pharmacology, complexing proteins

Introduction
Facial aging is a multifactorial process that is attributed to a combination of soft tissue atrophy, bone resorption and remodeling, muscular hypertrophy, and muscle imbalances. These facial changes are the result of intrinsic damage caused by genetics and hormonal and biochemical changes, and extrinsic damage related to a number of environmental factors, including gravity, smoking, and sun damage. In addition, the appearance of the face as it ages is also a direct result of the emotional expressions exhibited by the individual. The repeated display of emotions by the habitual use of specific facial muscles will eventually result in the appearance of hyperfunctional facial lines, which may give an erroneous and negative impression of emotions or personality characteristics.

During the fourth decade of life, several visible signs of aging begin to appear in the periorbital region, including eyelid laxity and glabellar furrows. In addition, gradual
descent of the eyebrow gives the appearance of smaller eyes. These changes become more pronounced as aging continues, and glabellar lines, along with other facial wrinkles and folds, remain noticeable and ingrained on the face even when the individual is at rest, instead of being dynamic and present only when communicating emotion.\(^2,^4\) Horizontal glabellar furrows are produced by the repeated action of the procerus muscle, whereas vertical kinetic lines and folds appear in the glabellar region due to repetitive activity of the corrugator superciliaris muscles, which originate from the medial end of the superciliary arch and extend out into the deep surface of the skin above the middle of the orbital arch. Along with the procerus and obicularis oculi muscles, the corrugator is responsible for the inferomedial pull of the eyebrows, giving rise to the expression of negative emotions such as anger and anxiety (Figure 1).\(^2,^5\) As well as giving the unintentional impression of negative emotional states, the persistent presence of glabellar frown lines can be suggestive of an older than actual age, affecting an individual’s self-perception, emotional well-being, and perception by others.\(^4,^6\) This perceived unwelcome characteristic of aging can have a considerable negative impact on an individual’s mood state and, for some individuals, could even contribute to the onset of depression. A single treatment with botulinum neurotoxin type A (BoNT/A) may reduce the symptoms of major depression.\(^7\)

**Overview of current strategies for the management of glabellar frown lines**

**Available treatment procedures**

The goal of treatment is to reduce the appearance of glabellar frown lines that suggest negative emotions such as anger or stress, but still allow an adequate degree of emotional expressivity. Methods of addressing glabellar frown lines consist of surgical interventions such as wire subscison,\(^8\) forehead lifting,\(^9,^{10}\) and the application of silicone implants.\(^11\) However, invasive surgical techniques are associated with prolonged recuperation times,\(^12\) potential complications, and adverse effects.\(^13\) Furthermore, surgery can be an extremely risky option for individuals merely seeking easily assessable cosmetic solutions. For these subjects, and for those who are precluded from, or contraindicated for, surgery, the availability of minimally invasive treatments such as dermal filling agents (eg, hyaluronic acid) and percutaneous selective radiofrequency nerve ablation\(^14–18\) has increased the number of treatment options for this indication. Nonetheless, the current nonsurgical treatments for prominent glabellar frown lines may have limitations, as most merely address symptoms and do not treat the origin of the wrinkle by correcting the defective underlying musculature. Although temporary plumping of facial lines can be achieved with fat implants, as with other fillers that are placed subdermally, this may be associated with possible vascular occlusion leading to infarction or embolic damage to the retina or optic nerve, which, in rare cases, can result in blindness.\(^5,^{19,20}\) Intradermal treatment is therefore preferred in order to avoid intravascular injection, although fat injections are now widely considered to be obsolete in this indication.

The use of botulinum neurotoxins produced by the various strains of the anaerobic bacterium *Clostridium botulinum* for the improvement of glabellar kinetic folds was first reported by Carruthers and Carruthers\(^13\) in 1992. Paralysis of the central brow musculature (corrugator, procerus, and medial orbicularis), and the subsequent unopposed action of the medial elevators of the brow, eliminated the presence of the muscles involved in glabellar frown lines. Reproduced with permission from Merz Pharmaceuticals GmbH.
of lines in the glabellar region and caused a temporary
medial brow lift. Treatment of the procerus is not always
necessary and need be injected only if there is evidence of
depressor activity. With its advantages including a rapid
onset of aesthetic results, and quick and straightforward
application, BoNT/A has since become the cornerstone
of minimally invasive aesthetic facial procedures, and its use
for the cosmetic treatment of glabellar frown lines is well
documented. In addition, BoNT/A injections are frequently
combined with volumizing treatments, such as injectable
fillers, soft tissue augmentation, contouring procedures,
including light-based and laser-based resurfacing, and
chemical peels, to boost outcomes and create a multifac-
eted, “whole face” approach to facial rejuvenation. It is
recommended that initial treatment should be performed
using BoNT/A alone in order to assess the need for any
further treatment of residual issues, such as static lines and
depressor activity. If these problems persist, combination treatment
with hyaluronic acid fillers can be undertaken at the next
session. In the author’s experience, injecting in two ses-
sions can help to avoid complications.

IncobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/
XEOMIN Cosmetic™; botulinum toxin type A [150 kDa];
Merz Pharmaceuticals GmbH, Frankfurt am Main,
Germany), a BoNT/A preparation that is free from
complexing proteins, is licensed in the US, Canada, Germany,
the UK, all other major European countries, and South
Korea for the treatment of glabellar frown lines, as well
as in Russia, Mexico, and Argentina for the treatment of
mimic wrinkles and hyperkinetic facial lines, respectively.
Two other BoNT/A preparations have been approved by
the US Food and Drug Administration for glabellar frown
lines: onabotulinumtoxinA (Botox Cosmetic®/Vistabel®;
Allergan, Irvine, CA) and abobotulinumtoxinA (Dysport®;
Ipsen Ltd, Slough, Berkshire, UK/Azzalure®; Galderma UK
Ltd, Watford, Hertfordshire, UK).

Administration of BoNT/A for glabellar
frown lines
A summary of the manufacturers’ recommendations for
the administration of each of the three approved BoNT/A
preparations for the treatment of glabellar frown lines is
provided in Table 1.

Reconstitution
Before application of BoNT/A for the treatment of glabellar
frown lines, reconstitution must be performed in accordance
with good clinical practice guidelines, particularly in respect
of aspesis. For incobotulinumtoxinA and onabotulinumtoxinA,
the manufacturers recommend that 50 unit (U) vials are
reconstituted prior to use in 1.25 mL of unpreserved
sodium chloride 9 mg/mL (0.9%) solution for injection,
corresponding to an active substance concentration of 4 U
per 0.1 mL. For abobotulinumtoxinA, 125 Speywood
U vials should be reconstituted using 0.63 mL of sodium
chloride (0.9%) solution for injection, which provides 125 U
of active substance at a concentration of 10 U per 0.05 mL of
reconstituted solution. The accurate measurement of 0.63 mL
can be achieved using 1 mL insulin-type syringes provided
by the manufacturer. However, in practice, physicians often
use their own preferred volume for reconstitution.

It is debatable whether dilution of BoNT/A preparations
has any effect on clinical efficacy, duration, and neurotoxin
spread. Higher dilutions are thought by some to be asso-
ciated with a greater risk of spread to nontargeted facial
muscles, poor clinical results, and shorter duration of treat-
ment effect. However, this belief is not shared by all
practitioners who use BoNT/A for cosmetic indications.
The question of whether the degree of dilution has any impact
on efficacy was investigated in a study by Prager et al., in
which 100 U incobotulinumtoxinA were diluted in 2.5 mL
(Group A) or 4 mL (Group B) sodium chloride solution
before administration of 25 U to 40 subjects with moderate-
to-severe glabellar frown lines. No significant differences
in efficacy were seen between the two concentrations.
Response rates for Group A versus Group B after 2 weeks,
3 months, and 4 months were 100% versus 89.5%, 84.2% versus
64.7%, and 53.3% versus 61.5%, respectively. Similar
efficacy results were reported in other studies investigating
onabotulinumtoxinA for glabellar frown lines; however,
these studies also reported that higher dilutions of onabotuli-
umtoxinA were associated with increased discomfort during
administration (as larger volumes of the preparation need to
be injected) and a higher incidence of eyelid ptosis.

Administration
Prior to injection, some physicians treat the injection area
with an antiseptic, and the author always uses an alcohol-
free disinfectant; however, this is not included in the
manufacturer’s instructions for onabotulinumtoxinA and
incobotulinumtoxinA. The instructions for abobotuli-
umtoxinA recommend the removal of any makeup and
disinfection of the skin with a local antiseptic. In general,
anesthesia (eg, topical cream) is not necessary prior to inject-
ing BoNT/A, but cooling with ice may be useful. Of a panel
of experts who convened to develop consensus guidelines
on the use of BoNT/A in facial aesthetics, 65% agreed that use of a topical anesthetic, including ice, was beneficial in some subjects. The treated area should not be massaged, and 78% of the panel members recommended that subjects should contract the injected muscles repeatedly for 90 minutes to 2 hours after treatment in an effort to expedite toxin uptake.

Generally, a five-injection approach is taken, with the total dose of BoNT/A divided equally between five sites in the glabellar region. The subject is first asked to frown, in order to allow easy location of the specific muscles. Once identified, the subject is asked to relax prior to the injection. One injection is administered to the procerus muscle, followed by one injection on each side of the face in the central part of the corrugator muscles, 1 cm above the bony orbital rim. Lastly, one injection is administered on each side in the lateral part of the corrugator muscles, 1 cm above the bony orbital rim (Figure 2). For male subjects, an additional injection may be performed on each side into the orbicularis, just above the eyebrow in the mid-pupillary line. Before and during the injection, the thumb and index finger should be used to apply firm pressure below the edge of the eye socket in order to prevent diffusion of the solution in this region. Superior and medial alignment of the needle should be maintained during the injection. For all three products, intramuscular injections should be performed using a sterile, thin (29–30 gauge) needle.

In order to achieve optimal results, tailoring the injection sites and doses to the subject’s anatomy is important. This was highlighted by a recent study that classified different patterns of glabellar frown lines, allowing the most important muscles involved in each pattern to be identified. This information allows a subject’s treatment to be optimized for their facial variations, with heavily used muscles receiving a larger dose or more injections, and lesser-used muscles receiving less to achieve a more natural look.

Dosing

The recommended standard total dose of 20 U of incobotulinumtoxinA for the treatment of glabellar frown lines, constituting a total injection volume of 0.5 mL, is divided equally and administered intramuscularly into each of the aforementioned five injection sites (0.1 mL per injection site; equivalent to 4 U incobotulinumtoxinA) according to the European label. The same standard dosing recommendations apply to onabotulinumtoxinA (European label). For abobotulinumtoxinA, a total dose of 50 U is recommended (0.25 mL of reconstituted solution) and divided between the five injection sites (0.05 mL per injection site; equivalent to 10 U abobotulinumtoxinA). According to the European label for abobotulinumtoxinA, in the event of treatment failure or diminished effect, no dose increase is recommended and alternative treatment methods should be employed.

For incobotulinumtoxinA, the dose can be increased to 30 U depending on the individual’s needs. If there is no treatment effect 1 month after injection, and the lack of effect is deemed to be due to insufficient dosage, then the dose can be adjusted and applied following a 3-month treatment interval. With onabotulinumtoxinA, if the standard 20 U dose does not result in significant improvement from baseline 1 month

<table>
<thead>
<tr>
<th>Manufacturer’s recommendations</th>
<th>IncobotulinumtoxinA</th>
<th>OnabotulinumtoxinA</th>
<th>AbobotulinumtoxinA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose for glabellar frown lines</td>
<td>20 U</td>
<td>20 U</td>
<td>50 U</td>
</tr>
<tr>
<td>Number of injection sites</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Volume administered per injection site</td>
<td>0.1 mL (4 U)</td>
<td>0.1 mL (4 U)</td>
<td>0.05 mL (10 U)</td>
</tr>
<tr>
<td>Needle size</td>
<td>30 G needle</td>
<td>30 G needle</td>
<td>29–30 G needle</td>
</tr>
<tr>
<td>Minimum treatment interval</td>
<td>3 months</td>
<td>3 months</td>
<td>3 months</td>
</tr>
</tbody>
</table>

Figure 2 Injection sites for treatment of glabellar frown lines. Reproduced with permission from Merz Pharmaceuticals GmbH.
after injection and the cause is thought to be insufficient dosage, then, according to the manufacturers, the dose can be increased to 40 U or 50 U, provided a 3-month treatment interval is observed.\(^7\)

For most subjects, 20 U of incobotulinumtoxinA or onabotulinumtoxinA is an appropriate starting dose and is commonly used in clinical trials.\(^6,39,41–44\) Clinical studies in subjects with glabellar frown lines have shown that there is no difference in efficacy between 20 U and 30 U doses of BoNT/A,\(^45,46\) and a recent study showed that a dose of onabotulinumtoxinA equivalent to 30 U was noninferior to a dose of incobotulinumtoxinA equivalent to 20 U.\(^22\) These findings demonstrate that a single dose of 20 U is appropriate in the majority of cases, and a greater effect cannot be achieved by increasing the dose. This conclusion has also been supported by the recent study by Moers-Carpi et al.\(^47\) and by the head-to-head study that demonstrates similar efficacy when incobotulinumtoxinA and onabotulinumtoxinA are applied using a 1:1 unit conversion ratio.\(^48\) However, higher doses can be appropriate for subjects, usually men, who tend to have a larger muscle mass,\(^28\) and consensus guidelines for the treatment of glabellar frown lines emphasize the need to individualize treatment, recommending onabotulinumtoxinA dose ranges of 10–30 U for women and 20–40 U for men for glabellar frown lines.\(^15\)

**Pharmacology of incobotulinumtoxinA compared with other BoNT/A preparations**

There are a number of pharmacologic differences between incobotulinumtoxinA and the other commercially available BoNT/A preparations. Table 2 provides a summary of the different formulations and the manufacturing characteristics.

**Mode of action and pharmacokinetics**

Pharmacologically, BoNT/A acts by blocking cholinergic neuromuscular transmission or cholinergic autonomic innervation of exocrine glands and smooth muscles by inhibiting the action of the soluble N-ethylmaleimide sensitive factor attachment protein receptor protein, SNAP-25, which is involved in fusion of acetylcholine-containing synaptic vesicles with the plasma membrane.\(^49–51\) The action of BoNT/A therefore inhibits the release of acetylcholine, resulting in nonresponse of the neuromuscular junction to nerve impulses (chemical denervation). The mechanism of action by which BoNT/A exerts its effects on cholinergic nerve terminals comprises four sequential steps: (1) the binding of the heavy chain of BoNT/A to glycolipids and the protein receptor SV2 on cholinergic terminals; (2) internalization of the toxin into the nerve terminal by endocytosis; (3) translocation of the neurotoxin’s light chain into the cytosol of the nerve terminal; (4) and cleavage of SNAP-25 by the light chain, causing inhibition of acetylcholine release.\(^49–52\) The effect of BoNT/A at the neuromuscular junction is only temporary, as the effect is terminated by the development of sprouts forming new synapses, which subsequently degenerate as the soluble N-ethylmaleimide sensitive factor attachment protein receptor protein complex is restored in the original nerve terminal.\(^49,50\) The effect of BoNT/A usually starts to decline after about 2.5 months.\(^49\) Internalized BoNT/A is degraded intracellularly, and any freely circulating BoNT/A molecules are phagocytosed or pinocytosed and degraded.\(^24\)

**Table 2** Summary of characteristics of botulinum neurotoxin type A products used in the treatment of glabellar frown lines\(^24,27,37,57,60,61,91\)

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>IncobotulinumtoxinA (Xeomin®/Bocouture®)</th>
<th>OnabotulinumtoxinA (Botox®/Vistabel®)</th>
<th>AbobotulinumtoxinA (Dysport®/Azzalure®)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merz Pharmaceuticals GmbH</td>
<td>Allergan Inc</td>
<td>Ipsen Inc/Medicis Inc</td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>900</td>
<td>500–700</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>364.3 ± 138.1 mm(^2) (per 5 U)</td>
<td>343.1 ± 110.7 mm(^2) (per 5 U)</td>
<td>459.1 ± 151.8 mm(^2) (per 12.5 U)</td>
<td></td>
</tr>
<tr>
<td>100/50</td>
<td>100/50</td>
<td>500/300</td>
<td></td>
</tr>
<tr>
<td>0.44 ng (CV = 1.9%)</td>
<td>0.73 ng (CV = 3.5%)</td>
<td>0.65 ng (CV = 11.4%)</td>
<td></td>
</tr>
<tr>
<td>227 U/ng</td>
<td>137 U/ng</td>
<td>154 U/ng</td>
<td></td>
</tr>
<tr>
<td>1:1</td>
<td>1:1</td>
<td>1:2.5–3</td>
<td></td>
</tr>
<tr>
<td>20 U</td>
<td>20 U</td>
<td>50 U</td>
<td></td>
</tr>
<tr>
<td>3 years</td>
<td>3 years</td>
<td>2 years</td>
<td></td>
</tr>
<tr>
<td>Up to 25°C (no refrigeration required)</td>
<td>2°C–8°C (refrigeration required)</td>
<td>2°C–8°C (refrigeration required)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: CV, coefficient variant.
It is not possible to perform classic pharmacokinetic and distribution studies of BoNT/A, because such small quantities (picograms per injection) of the active substance are applied and it rapidly and irreversibly binds to cholinergic nerve terminals.24

Complexing proteins
The most notable difference between incobotulinumtoxinA and the other two BoNT/A preparations is that incobotulinumtoxinA is specifically purified and is thus free from complexing proteins. Native botulinum toxin is a high-molecular-weight complex (900 kDa or smaller) in which the neurotoxin (150 kDa) is noncovalently attached to additional nontoxic proteins (hemagglutinin and nonhemagglutinin clostridial proteins).53,54 During the manufacturing process for incobotulinumtoxinA, these complexing proteins are separated and discarded from the neurotoxin during a number of purification steps. The resulting active ingredient of incobotulinumtoxinA represents the pure neurotoxin (150 kDa) that is free from complexing proteins.24,54

The biologically active component of the high-molecular-weight complex is the 150 kDa neurotoxin,24 and the complexing proteins do not appear to contribute to the therapeutic effect of BoNT/A treatment.55 Furthermore, recent investigations have determined that complexing proteins in BoNT/A preparations have no beneficial role and do not appear to affect the spread of the toxin from the injection site.56,57 A study by Eisele et al58 determined that rapid dissociation of the BoNT/A complexes in onabotulinumtoxinA and abobotulinumtoxinA occurs at neutral to basic pH values, with up to 80% of the neurotoxin being released within 1 minute once this pH threshold is achieved. The presence of complexing proteins had previously been thought to protect the neurotoxin from harsh environmental conditions (eg, low intragastral pH after oral ingestion);59 however, in real-time and accelerated stability studies, incobotulinumtoxinA was found to be stable without refrigeration for 48 months and was not affected by short-term temperature stress up to 60°C, demonstrating that complexing proteins are not required for product stability.60

Active/inactive neurotoxin
A recent study investigating the amount of BoNT/A protein found in incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA revealed that, in addition to containing only the neurotoxin without extraneous clostridial proteins, incobotulinumtoxinA is likely to contain only active neurotoxin; in contrast, onabotulinumtoxinA is likely to contain additional denatured/inactive neurotoxin, possibly due to the use of sodium chloride, which seems to be detrimental for activity during the drying process.61 The results suggest that an increased percentage of denatured/inactivated neurotoxin, approximately 60%, is delivered with onabotulinumtoxinA compared with incobotulinumtoxinA when the same dosage is applied to achieve the same clinical effect. Because denatured/inactive protein cannot contribute to the clinical effect, it merely represents an unnecessary additional foreign protein load. A higher dose of antigen may increase the risk of formation of neutralizing antibodies and lead to therapy failure, as discussed here.61

Immunogenicity
As botulinum toxins consist of foreign proteins, there is a possibility that development of antibodies against the neurotoxin may occur. The presence of nontoxic complexing proteins in onabotulinumtoxinA and abobotulinumtoxinA represents an additional foreign protein load, which may increase the potential for eliciting an immune response.62 The formation of neutralizing antibodies against the toxin blocks the action of BoNT/A, resulting in partial or total antibody-induced therapy failure.33,49

The use of onabotulinumtoxinA and abobotulinumtoxinA for aesthetic purposes may result in the development of antibodies and treatment resistance.63–66 Preclinical studies have shown that, in contrast to onabotulinumtoxinA and abobotulinumtoxinA, incobotulinumtoxinA did not lead to the production of neutralizing antibodies following repeated injections into New Zealand white rabbits.55,67 The preclinical results suggest that the risk of antibody formation is lower for incobotulinumtoxinA compared with other formulations that contain complexing proteins, a conclusion also drawn from a review of the data on the use of incobotulinumtoxinA in focal dystonias.68 An ongoing study of incobotulinumtoxinA for cervical dystonia in treatment-naïve patients and those who had received prior treatment with other BoNT/A formulations showed no development of neutralizing antibodies following continuous treatment with incobotulinumtoxinA during the first 2 years of the study.69 In addition, a reduction in the amount of clostridial protein per 100 U vial of a BoNT/A preparation led to a decrease in the number of nonresponders70 and the risk of antibody formation,71 indicating a relationship between a lower clostridial protein content of BoNT/A preparations and a lower risk of neutralizing antibody formation.
Neurotoxin potency

In the aforementioned study by Frevert, in vitro biochemical assays were performed to determine the overall mean concentration of the 150 kDa neurotoxin present in incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA; these results were then used to calculate the specific neurotoxin potency (defined as the potency or biologic activity [units] per mass of neurotoxin protein [ng]) of these preparations. IncobotulinumtoxinA was found to contain a mean concentration of neurotoxin (0.44 ng per 100 U vial) and the highest specific neurotoxin potency (227 U/ng), followed by abobotulinumtoxinA (0.65 ng per 100 U; 154 U/ng) and, lastly, onabotulinumtoxinA (0.73 ng per 100 U vial; 137 U/ng) (Figure 3). Given that the clostridial protein content per 100 U for onabotulinumtoxinA is 5 ng and for abobotulinumtoxinA is 0.87 ng, the specific biologic potencies relative to total foreign protein are 20 U/ng and 115 U/ng, respectively, compared with 227 U/ng for incobotulinumtoxinA.

Although differences in neurotoxin-specific activity between the BoNT/A preparations were seen in the Frevert study, other assay procedures can be used to determine biologic activity. In another recent study, the neurotoxin potency of incobotulinumtoxinA and onabotulinumtoxinA was measured using a standardized LD50 mouse assay and the same dilution factor between doses for each product. No statistically significant difference in potency was detected between these BoNT/A preparations. The biologic potencies were well within the range of 100 mouse U ±25%, −20% as stipulated by the European Pharmacopoeia; the mean potency of onabotulinumtoxinA (in mouse U ± standard deviation) was 103.1 ± 6.5, whereas that for incobotulinumtoxinA was 101.7 ± 6.2. The conclusion was that onabotulinumtoxinA and incobotulinumtoxinA can be compared using a 1:1 conversion ratio, allowing easy exchange of both products in the standard aesthetic clinical setting.

This finding is supported by a clinical trial showing that, when administered at the same dose, incobotulinumtoxinA is noninferior to onabotulinumtoxinA for the treatment of glabellar frown lines.

Toxin spread and area of efficacy

The precise localization of BoNT/A during treatment of glabellar frown lines is imperative to prevent spread of the neurotoxin to (and subsequent paralysis of) nearby untargeted muscles, as this can lead to adverse events such as eyelid ptosis. Consequently, the toxin spread of BoNT/A preparations is of important clinical relevance, particularly when selecting the most appropriate treatment. A number of studies have been conducted to assess the area of efficacy of BoNT/A preparations. As inhibition of acetylcholine release by these agents inhibits endocrine glands, resulting in the cessation of sweating, the area of anhidrosis that is produced gives an indication of the area of spread. Consequently, studies that assess toxin spread are based on the hypothesis that the size of the anhidrotic area correlates with the size of the area of reduced muscle action and clinical effect. One recent study compared the spread of incobotulinumtoxinA (5 U) versus onabotulinumtoxinA (5 U) and abobotulinumtoxinA (12.5 U) at a 1:1:2.5 dose conversion ratio. At 6 weeks after injection of each agent in an identical volume (0.125 mL) into the forehead of 29 subjects, the size of the anhidrotic halos (ie, mean maximal area of anhidrosis) was found to be comparable between incobotulinumtoxinA and onabotulinumtoxinA (364.3 ± 138.1 mm2 vs 343.1 ± 110.7 mm2, respectively). However, the maximal area of anhidrosis observed with abobotulinumtoxinA (459.1 ± 151.8 mm2) was larger than that of incobotulinumtoxinA. When the spread of each agent over time was assessed, the area under the effect curve over 6 months for incobotulinumtoxinA was again comparable with that of onabotulinumtoxinA and smaller than that of abobotulinumtoxinA. These results showed that incobotulinumtoxinA has a similar spread to that of onabotulinumtoxinA and a smaller one than abobotulinumtoxinA, also indicating that the presence of complexing proteins does not affect toxin spread. This finding is not surprising, given that dissociation of protein complexes is rapid at physiologic pH. As the authors of this study highlight, for treatment of glabellar frown lines a total dose of 20 U incobotulinumtoxinA and onabotulinumtoxinA is recommended by their respective manufacturers, compared with a dose of 50 U recommended by the manufacturer of abobotulinumtoxinA. The dose of abobotulinumtoxinA

![Figure 3: Amount of clostridial protein and neurotoxin per 100 U of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.](https://www.dovepress.com/clinical-pharmacology-advances-and-applications-dovepress.com)
appears to result in a wider spread than that of the other two agents and therefore has the potential to cause an increased risk of side effects due to migration into adjacent nontarget muscles.\textsuperscript{57}

**Clinical use and efficacy, safety, and tolerability of incobotulinumtoxinA**

**Phase III clinical trials**

**Randomized placebo-controlled trials**

A number of Phase III placebo-controlled trials of incobotulinumtoxinA have been conducted, with consistently favorable results. In two recent identically designed, randomized, double-blind, placebo-controlled, Phase III studies, subjects ($\geq 18$ years of age) with moderate-to-severe glabellar frown lines (score of 2 or 3 on the 4-point facial wrinkle scale (FWS), assessed at maximum frown, were treated with a single injection of 20 U incobotulinumtoxinA or placebo for a period of 120 days.\textsuperscript{42,43} A total of 547 subjects were enrolled across these two Phase III studies, and efficacy was assessed using the new, rigorous composite endpoint of treatment success (CETS), reflecting the Food and Drug Administration’s interest in identifying substantial improvements after treatment. Responders were defined as those with a $\geq 2$-point improvement compared with baseline at maximum frown at Day 30 by the investigator’s rating on the FWS and by the subject’s assessment on a 4-point scale. Therefore, a subject was a responder only if both criteria were fulfilled. In both studies, treatment with a single dose of incobotulinumtoxinA was found to be superior to placebo ($P < 0.0001$), according to the CETS (60.3\% vs 0\%;\textsuperscript{42} 47.8\% vs 0\%).\textsuperscript{43} The individual components of the CETS also demonstrated superiority of incobotulinumtoxinA over placebo in both studies. Investigator assessment on the FWS at maximum frown at Day 30 revealed a $\geq 2$-point improvement compared with baseline in 76.6\%\textsuperscript{42} and 70.9\%\textsuperscript{43} of subjects in the incobotulinumtoxinA groups compared with 0\% in the placebo groups in each study ($P < 0.0001$ for both comparisons).

Results for secondary endpoints (reduction in investigator-rated score to “none” [0] or “mild” [1], and a reduction from baseline of at least 1 point in severity rating), which were based on the previously accepted standards for assessing treatment efficacy, confirmed the primary endpoint findings. Defining a treatment response as a composite of both an investigator-assessed $\geq 2$-point improvement from baseline on the FWS and a subject-assessed 4-point scale, allows for a more robust definition of a responder. Because only subjects fulfilling both of these two criteria were considered responders on the CETS, these new assessments represent the most stringent applied to date in placebo-controlled studies of BoNT/A for treatment of glabellar frown lines.\textsuperscript{42,43}

In both trials, the incidence of adverse events (AEs) deemed to be related to incobotulinumtoxinA treatment was low (7.1\%;\textsuperscript{42} 12.1\%\textsuperscript{43}), with headache being the most commonly reported AE (3.8\% and 7.1\% in each study, respectively). Overall, serious AEs were experienced by three subjects receiving incobotulinumtoxinA; one of these led to discontinuation of treatment but was not treatment related. The development of neutralizing antibodies was not observed in any subject treated with incobotulinumtoxinA.

**Head-to-head trials**

Sattler et al\textsuperscript{74} reported results from a much anticipated large, Phase III, rater- and subject-blind, noninferiority study of incobotulinumtoxinA and onabotulinumtoxinA. A total of 381 women (aged 18–50 years) with moderate-to-severe glabellar frown lines were randomized in a 3:1 ratio to receive 24 U incobotulinumtoxinA or 24 U onabotulinumtoxinA, respectively. The 24 U dose was chosen, as it was the average dose used by physicians for the treatment of glabellar frown lines in clinical practice. High response rates (response defined as an improvement of $\geq 1$ point on the FWS) of 96.4\% and 95.7\% at maximum frown were seen at 4 weeks post injection in the incobotulinumtoxinA and onabotulinumtoxinA groups, respectively, and remained high at 12 weeks (80.1\% in the incobotulinumtoxinA group and 78.5\% in the onabotulinumtoxinA group). Statistical analysis confirmed noninferiority of incobotulinumtoxinA to onabotulinumtoxinA at both time points. Although lower rates were seen at rest, results were still comparable between the two treatment groups. Consistently high responses were also seen on the subject self-assessment of treatment using the FWS (response defined as an improvement of $\geq 1$ point compared with baseline), with 93.9\% of the subjects treated with incobotulinumtoxinA versus 93.5\% of those treated with onabotulinumtoxinA showing a response at Week 4 at maximum frown. Similarly, when using the Patient’s Global Assessment (PGA) of change in appearance of glabellar frown lines compared with the situation immediately before injection, 93.5\% of the subjects in the incobotulinumtoxinA group and 92.5\% of subjects in the onabotulinumtoxinA group were responders (defined as those with a score of at least +2 points) at Week 4, again confirming noninferiority of incobotulinumtoxinA to onabotulinumtoxinA. Comparable results for tolerability were also seen, with 3.2\% and 5.2\% of subjects experiencing treatment-emergent AEs related to treatment in the incobotulinumtoxinA and
onabotulinumtoxinA groups, respectively. For both treatments, headache was the most commonly reported treatment-related AE (1.8% vs 2.1%, respectively). One case of eyelid ptosis was reported in the onabotulinumtoxinA group, which later resolved. Neutralizing antibodies to either treatment were not observed.

The purpose of noninferiority trials is to evaluate whether a new treatment is no worse than an existing active comparator by a specified margin called the equivalence margin. Any improvement seen with the new treatment still lies within the definition of noninferiority; therefore, the conclusion of noninferiority does not rule out possible superiority of the new treatment.

A double-blind, randomized trial was conducted by Rapp et al., in which 120 subjects with mild-to-severe glabellar frown lines were treated with 21 U incobotulinumtoxinA, 21 U onabotulinumtoxinA, or 63 U abobotulinumtoxinA. This study assessed the onset and duration of efficacy of these three products; the findings are discussed in a later section.

**Open-label trials**

A recent prospective, open-label, Phase III, single-arm study was conducted to determine the efficacy of incobotulinumtoxinA for the treatment of glabellar frown lines. A total of 105 subjects (aged 18–65 years) with moderate-to-severe glabellar frown lines at maximum frown, on the FWS, were treated with 20 U incobotulinumtoxinA, divided between five injection sites, and assessed over 84 days. A high proportion of responders (defined as subjects with an improvement of ≥1 on the FWS when compared with Day 0) were observed at 28 days (98.1%) and 84 days (80.0%) post injection. Additionally, subjects also rated treatment success highly, with 98.1% and 85.6% of subjects achieving a score of at least +2 points on the PGA, on Days 28 and 84, respectively. In this study, incobotulinumtoxinA demonstrated favorable tolerability, with only 3.8% of subjects experiencing a treatment-emergent AE that was deemed related to treatment. The development of neutralizing antibodies against incobotulinumtoxinA was not observed.

The long-term efficacy of incobotulinumtoxinA was evaluated by Rzany et al. in a prospective, open-label, multicenter, repeat-dosing, Phase III extension trial that recruited subjects from the two Phase III placebo-controlled trials, along with subjects from two other randomized, placebo-controlled trials. A total of 801 subjects with moderate-to-severe glabellar frown lines on the FWS at baseline received up to eight cycles of incobotulinumtoxinA treatment in a period not exceeding 2 years; the treatment interval was at least 85 days. Response rates (defined as subjects with glabellar line severity of none [0] or mild [1] at maximum frown on the FWS) were high and remained high for up to eight treatment cycles, ranging from 79.1% to 89.6%. Subject self-assessment of efficacy was also maintained over the cycles of treatment, with response rates (the proportion of subjects with ≥1-point improvement on a 4-point scale compared with Day 0) ranging from 85.9% to 93.8%. This study demonstrated the long-term efficacy of incobotulinumtoxinA and also showed that repeat dosing is effective, with a trend toward increasing response rates that were consistently high for up to eight regular cycles of treatment. Notably, the incidence of treatment-emergent AEs during this extended period was low. The majority of events reported were mild-to-moderate in nature. No serious AEs related to the study drug were reported and no neutralizing antibodies were detected. This was the first long-term study that resembles the repeated usage of incobotulinumtoxinA in the clinical setting.

**Other clinical trials**

In a study conducted by Schleyer and Berneburg, ten female subjects were treated with 20–23 U incobotulinumtoxinA in the glabellar region. After 2 weeks, 90% of subjects responded “well” or “very well” to the treatment. The effect of treatment was sustained in the majority of subjects (89%) at Week 12. Treatment was well tolerated, with only one case of headache being reported (this resolved on the same day as treatment administration).

**Studies investigating the onset and duration of effect of BoNT/A**

Time to onset and duration of effect are important factors that may influence subject satisfaction with cosmetic treatments, as they have an impact on cost and convenience. Results from randomized clinical trials of incobotulinumtoxinA have shown that improvement in the severity of glabellar frown lines is usually observed within 2 to 3 days post treatment, and the maximum effect is seen after 30 days. This rapid onset of treatment effect does not appear to be diminished by repeated administration of incobotulinumtoxinA, as demonstrated in the long-term extension study, where onset of effect occurred within the “first few days” after treatment for each of the eight treatment cycles.

Few studies have been conducted to specifically examine the onset and duration of effect of BoNT/A preparations. Two recent studies have investigated the
onset and durability of the effect of incobotulinumtoxinA. In a single-arm, prospective, proof-of-concept study conducted by Prager et al, glabellar frown lines were treated with 25 U incobotulinumtoxinA in 23 subjects who were assessed over a 5-month period. At 2–4 days after treatment, a high proportion (95.2%) of subjects were responders when treatment response was defined as subjects with a ≥1-point improvement on the Merz 5-point scale at maximum frown, compared with baseline. The responder rate, according to this definition, was 100% for the next three visits until Visit 6 (16–17 weeks post treatment), when it decreased to 94.7%. The persistence of the treatment effect (ie, ≥1-point improvement from baseline) was also evident for up to 5 months following treatment, when over 75% of subjects were still responders at maximum frown. During this time period, responder rates were higher for glabellar lines at maximum frown than for glabellar lines at rest. When responders were defined as subjects with a ≥2-point improvement on the Merz 5-point scale at maximum frown, 85.0% of subjects were classed as responders 2–4 days after treatment; this rate increased to 100% at Visit 3 (Day 8 ± 1) and Visit 4 (Day 14 ± 2), decreasing to 78.9% at Visit 5 (12–13 weeks post treatment), 50% at Visit 6 (16–17 weeks post treatment), and 20% at Visit 7 (20–21 weeks post treatment). For glabellar frown lines at rest, no subjects were responders at any time point using this more stringent definition of response, probably due to the low baseline scores for glabellar frown lines at rest. An early onset of treatment effect was observed in this trial, with 84% of the maximum effect of incobotulinumtoxinA at maximum frown occurring 2–4 days after injection. In subject self-assessments, 18% of subjects rated their appearance as younger than their actual age at baseline compared with 73% at Visit 4 (Day 14 ± 2) post treatment. Additionally, the majority of subjects rated their glabellar frown lines as “improved” or “markedly improved” compared with baseline at Visits 2 (Day 3 ± 1), 3 (Day 8 ± 1), and 4 (Day 14 ± 2).

In a double-blind randomized study of 120 subjects, Rappl et al compared the onset and duration of incobotulinumtoxinA (21 U), onabotulinumtoxinA (21 U), and abobotulinumtoxinA (63 U). IncobotulinumtoxinA had the most rapid onset of effect, with 95% of subjects achieving an effect on Day 4 compared with only 41% and 35% in the onabotulinumtoxinA and abobotulinumtoxinA groups, respectively. Although the longest duration of effect was seen with incobotulinumtoxinA, this was not statistically significant. For incobotulinumtoxinA, 13% of subjects still showed an effect at Day 180 compared with 3% and 5% in the onabotulinumtoxinA and abobotulinumtoxinA groups, respectively.

Dosing of incobotulinumtoxinA in clinical trials

Units of BoNT/A products are not considered to be interchangeable due to the different assays used by the manufacturers to assess potency and monitor quality. However, a 1:1 dose ratio between incobotulinumtoxinA and onabotulinumtoxinA is often suggested, which would seem appropriate considering the evidence for noninferiority of incobotulinumtoxinA to onabotulinumtoxinA at the same dosage for the treatment of glabellar frown lines. In addition, a recent meta-analysis of clinical and preclinical data from eleven trials comparing incobotulinumtoxinA and incobotulinumtoxinA concluded that there was no difference in the relative potency of the two products, and that they should continue to be used at a 1:1 dose ratio.

In studies of incobotulinumtoxinA for treatment of glabellar frown lines, the doses investigated have ranged from 20 U (as recommended by the manufacturer) to 24 U (as used in the head-to-head noninferiority study against onabotulinumtoxinA). There has been some debate regarding whether increasing the dose above the recommended 20 U of either incobotulinumtoxinA or onabotulinumtoxinA for treatment of glabellar frown lines will achieve better results, or if there is a ceiling effect preventing any further improvement of treatment outcomes. In a split-face study by Prager and Rappl, which omitted treatment of the procerus muscle, 35 subjects with symmetrical moderate-to-severe glabellar frown lines on the Merz 5-point scale were treated with either incobotulinumtoxinA or onabotulinumtoxinA using a dose-conversion ratio of 1:1.5 (incobotulinumtoxinA:onabotulinumtoxinA) and assessed for 4–6 months. IncobotulinumtoxinA treatment consisted of two injections of 4 U (equivalent to 20 U when corrugator muscles on both sides and the procerus muscle are treated), whereas onabotulinumtoxinA treatment consisted of two injections of 6 U (equivalent to 30 U in total when corrugator muscles on both sides and the procerus muscle are treated). The split-face design of this study facilitated intraindividual comparison between the two products, due to the ease of identifying any asymmetry, which would indicate a difference in efficacy of the two products. This meant that a smaller number of patients was sufficient to generate statistically significant results. Response rates (defined as ≥1-point improvement from baseline) were the same in both groups throughout the study period (100% at Week 4, 81% at Month 4, and 50% at Month 6). Therefore, noninferiority
of the 50% higher dose of onabotulinumtoxinA to that of incobotulinumtoxinA was confirmed at 4 weeks, 4 months, and 6 months post treatment.

Although a 1:1 dose ratio for incobotulinumtoxinA: onabotulinumtoxinA is widely accepted as appropriate, a standardized conversion ratio between incobotulinumtoxinA or onabotulinumtoxinA and abobotulinumtoxinA has not yet been determined. For therapeutic indications such as cervical dystonia, onabotulinumtoxinA: abobotulinumtoxinA conversion ratios of up to 1:11 have been used in the past. However, more recent evidence suggests that lower conversion ratios (below 1:3) are preferable in clinical dermatology, and for glabellar frown lines, relative strength of action has been suggested to be 1:2 to 1:4 (onabotulinumtoxinA/incobotulinumtoxinA: abobotulinumtoxinA).

Subject satisfaction and acceptability

Subject assessment of treatment outcomes

The use of subject-assessed treatment outcomes is becoming increasingly common in clinical trials. In trials investigating BoNT/A treatment for glabellar frown lines, subject-reported outcomes help to assess subject satisfaction with their treatment, which is of crucial importance in aesthetics. In clinical trials of incobotulinumtoxinA, subject assessment is often carried out using a 4-point Patient Assessment Scale (PAS), for which subjects respond, at rest, to the question “How would you judge the degree of your glabellar lines by comparison with sample photos at this visit?”, with potential rating responses being: 0 = no visible vertical line(s) at all, 1 = slightly visible vertical line(s), 2 = moderate vertical line(s) with depression, and 3 = deep vertical line(s) and depression that cannot be effaced by spreading, and, at maximum frown, to the question “How would you judge the potency of frown muscle action by comparison with sample photos at this visit?”, with potential rating responses being: 0 = no muscle action at all, 1 = some even slight muscle action possible, 2 = moderately strong muscle action possible, and 3 = strong muscle action possible, which may cause local pallor. In some trials, subject self-assessment has been performed using the 9-point PGA, in response to the question “How would you rate the change in the appearance of your glabellar lines compared with the situation immediately before the injection?”. The potential PGA rating responses are: +4 = complete improvement, +3 = marked improvement, +2 = moderate improvement, +1 = slight improvement, 0 = unchanged, −1 = slight worsening, −2 = moderate worsening, −3 = marked worsening, and −4 = very marked worsening. The long-term incobotulinumtoxinA study also included a 6-point Likert-type subject assessment scale to subjectively assess glabellar frown lines, with subjects asked to assess the degree of their glabellar frown lines at maximum frown and at rest using the ratings 0 = none at all to 5 = very deep, with intervening grades not having specific descriptions.

Subject satisfaction with incobotulinumtoxinA

As discussed previously, high levels of subject satisfaction have been reported in clinical trials of incobotulinumtoxinA for glabellar frown lines. In the two randomized Phase III trials, in which a responder on the PAS was defined as a subject with ≥1-point improvement compared with baseline

![Figure 4](https://www.dovepress.com/)

**Figure 4.** Subject assessment of response with 20 U, using a 4-point scale where a responder was defined as a subject with at least a 1-point improvement compared with baseline at Day 30 from two Phase III, placebo-controlled trials: (A) Carruthers et al,46 full-analysis set; and (B) Hanke et al,47 full-analysis set, observed cases.
Conclusion

IncobotulinumtoxinA has many benefits for the treatment of glabellar frown lines. It differs from other commercially available BoNT/A preparations in that, due to its specific purification process, incobotulinumtoxinA is free from complexing proteins and contains only active neurotoxin, thereby reducing the foreign protein load to a minimum and minimizing the risk of neutralizing antibody production. In practical terms, it has a long shelf-life, remaining stable without the need for refrigeration, and, due to its limited ability to spread, is a precise, localized treatment. Clinical trial data have demonstrated that incobotulinumtoxinA is an effective and well-tolerated treatment for glabellar frown lines at 20 U, with rapid onset, long duration of effect, and high subject satisfaction, and that a unit conversion ratio between incobotulinumtoxinA and onabotulinumtoxinA of 1:1 is appropriate.

Acknowledgment

Editorial assistance was provided by Ogilvy 4D, Oxford, UK, and funded by Merz Pharmaceuticals GmbH.

Disclosure

Welf Prager has acted as a consultant and lecturer for Allergan Inc, Merz Pharmaceuticals GmbH, and Galderma Pharma SA.

References

18. Nahai FR. Update on radiofrequency ablation of the frontal branch to the corrugator muscles to reduce glabellar frown lines. Plast Reconstr Surg. 2010;125(5):208e.
52

Clinical Pharmacology: Advances and Applications

Publish your work in this journal

Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of drug experience in humans. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Submit your manuscript here: http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal

Dovepress

Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.